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Abstract 1 
Over the past decade glial cells have attracted attention for harboring unexploited targets for drug 2 
discovery. Several glial targets have attracted de novo drug discovery programs, as highlighted in this 3 
GLIA Special Issue. Drug repurposing, which has the objective of utilizing existing drugs as well as 4 
abandoned, failed, or not yet pursued clinical development candidates for new indications, might 5 
provide a faster opportunity to bring drugs for glial targets to patients with unmet needs. Here we 6 
review the potential of the intermediate-conductance calcium-activated potassium channels KCa3.1 as 7 
the target for such a repurposing effort. We discuss the data on KCa3.1 expression on microglia in vitro 8 
and in vivo. We review the relevant literature on the two KCa3.1 inhibitors TRAM-34 and Senicapoc. 9 
Finally, we provide an outlook of what it might take to harness the potential of KCa3.1 as a bona fide 10 
microglial drug target.  11 
12 
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 1 
DRUG REPUROSING FOR GLIAL CELLS 2 
Drug repurposing, also called drug repositioning, has the objective of utilizing existing drugs and failed, 3 
abandoned, or not yet pursued clinical development candidates for new indications (Langedijk et al., 4 
2015). This concept has gained increasing traction in the recent years and has been considered for 5 
infectious disease, oncology, orphan diseases, as well as CNS indications such as Alzheimer’s disease, 6 
stroke and pain (Corbett et al., 2012; Corbett et al., 2015; Fagan, 2010; Gupta et al., 2013; Sardana et al., 7 
2011; Sisignano et al., 2015; Wurth et al., 2016). In fact, the National Center for Advancing Translational 8 
Sciences (NCATS) at the US National Institutes of Health (NIH) has set up the “Discovering New 9 
Therapeutic Uses for Existing Molecules (New Therapeutic Uses)” initiative, which is a “collaborative 10 
program designed to develop partnerships between pharmaceutical companies and the biomedical 11 
research community to advance development of therapeutics. This innovative program matches 12 
researchers with a selection of pharmaceutical industry assets to test ideas for new therapeutic uses, 13 
with the ultimate goal of identifying promising new treatments for patients.” While there is increasing 14 
activity in developing drugs to target glial cells, highlighted by this GLIA Special Issue, could repurposing 15 
of existing drugs or clinical-grade compounds accelerate therapeutic opportunities for targeting glia?  16 
Considering that macroglia share the same neurotransmitter receptors as neurons, this question might 17 
seem obvious. Indeed, it cannot be excluded that of the multitude of approved drugs targeting 18 
glutamate receptors some of their activity might actually originate from glial glutamate receptors 19 
(Hubbard et al., 2013; Nicoletti et al., 2015). However, the more specific question is, whether there are 20 
drugs or drug-candidates that could be repurposed to address a specific glial hypothesis? Considering 21 
that microglia share a molecular repertoire with other immune cells, specifically macrophages and 22 
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monocytes, are there any current therapeutic entities which could be repurposed? For example, CD33 1 
antibodies where originally developed against acute myeloid leukemia (AML) (Grosso et al., 2015; Jurcic, 2 
2012). However, the recent interest in CD33 as a microglia target involved in Alzheimer’s disease (AD) 3 
pathology has sparked interest in these antibodies as potential repurposing opportunity for the 4 
treatment of AD (see Wes et al. this GLIA Special Issue).  5 
Ion channels have received considerable consideration as promising drug targets on microglia (Biber et 6 
al., 2016; Eder, 2010; Okuse, 2007; Skaper, 2011) Bhattacharya and Biber this GLIA Special Issue). Of 7 
these the calcium-activated potassium channel KCa3.1 has received increasing attention (Chen et al., 8 
2015a; Feske et al., 2015; Lam and Wulff, 2011; Maezawa et al., 2012; Staal et al., unpublished 9 
observation; Wulff and Castle, 2010).  10 
KCa3.1 11 
The family of calcium-activated potassium channels (KCa channels) has two groups (Wei et al., 2005) 12 
Large conductance (BK, 100-220 pS) channels which are gated by a combination of of intracellular 13 
calcium concentration and membrane potential; and the intermediate conductance (IK, 20-85 pS) and 14 
small conductance (SK, 2-20pS) channels which are more sensitive to and solely gated by internal 15 
calcium ions. The KCNN4 gene coding for KCa3.1 was independently cloned by three groups in 1997 (Ishii 16 
et al., 1997; Joiner et al., 1997; Logsdon et al., 1997). It is also known as IK1; IKCa1, ; SK4, SKCa4; and 17 
Gardos channel). KCa3.1. is widely expressed in non-excitable cells including immune cells such as T-cells, 18 
macrophages and reactive microglia (Feske et al., 2012; Feske et al., 2015; Wulff and Castle, 2010)   19 
 20 
KCa3.1 IN MICROGLIA in vitro 21 
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Voltage-independent KCa3.1-like Ca
2+
 activated K
+
 currents were reported first in cultured mouse 1 
microglial cells in 1997 (Eder et al., 1997), while expression of KCa3.1 on the mRNA level was confirmed 2 
later in rat and mouse microglia in vitro (Khanna et al., 2001). Voltage-independent KCa3.1-like Ca
2+
 3 
activated K
+
 currents could be inhibited by charybdotoxin and clotrimazole, but remained unaffected by 4 
paxilline or apamin, inhibitors of large conductance (BK-type) and small conductance (SK-type) Ca
2+
 5 
activated K
+
 channels, respectively (Schilling et al., 2002; Schilling et al., 2004).  Furthermore, 6 
charybdotoxin and clotrimazole were found to prevent phorbol 12-myristate 13-acetate (PMA)-induced 7 
microglial oxidative burst (Khanna et al., 2001) as well as lysophosphatidic acid-induced microglial 8 
migration (Schilling et al., 2004). Together, these data suggested that KCa3.1 is functionally active in 9 
microglia and is the predominant Ca
2+
 activated K
+
 channel in microglia in vitro. 10 
Following up on these initial reports, Kaushal et al. (Kaushal et al., 2007) compared expression of KCa3.1 11 
between neuronal, astrocyte and microglial cultures. The reported a much higher mRNA expression in 12 
microglial cultures than in neuronal or astrocytic cultures. The expression level was not increased by 13 
stimulation with lipopolysaccharide (LPS), a frequently used “activator” of microglial cells. In addition, 14 
the authors showed positive immunofluorescence staining for KCa3.1 (rabbit polyclonal KCa3.1/SK4 15 
antibody, Alomone Labs) in microglial cultures.  However, staining in neuronal or astrocyte cultures or 16 
relevant controls were not shown. Furthermore, using electrophysiology readouts the authors described 17 
Ca2+ activated K
+
 current characteristic of KCa3.1 which was inhibited by the KCa3.1.1 inhibitor TRAM-34 18 
(see section below). In neuronal/microglia co-culture experiments TRAM-34 reduced LPS-induced 19 
microglial neurotoxicity, presumably via reduction of p38-dependent nitric oxide (NO) production 20 
(Kaushal et al., 2007).  21 
Subsequently, a series of reports from the same group expanded on these observations. Using 22 
electrophysiology and TRAM-34 as an inhibitor for KCa3.1 the authors reported that microglia stimulation 23 
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with UTP triggered KCa3.1 activation (Ferreira and Schlichter, 2013). The KCa3.1 activation was dependent 1 
on substantial increases in intracellular calcium achieved by triggering purinergic-receptor mediated 2 
release of calcium from intracellular stores, followed by store-operated calcium entry. Thus, the KCa3.1 3 
activation hyperpolarized the cells and increased the driving force for calcium entry via Ca
2+
-release 4 
activated calcium (CRAC) channels and subsequent refilling of intracellular calcium stores (Feske et al., 5 
2012). Furthermore, the authors reported expression of KCa3.1 by immunofluorescence in the rat 6 
microglia cell line MLS-9 (anti-KCa3.1 (SK4) rabbit polyclonal antiserum, Abcam); however, no controls 7 
were shown. In the second study, IL-4 treatment led to an increase of KCa3.1 mRNA in cultured rat 8 
microglia after 6 hours (Ferreira et al., 2014). This correlated with a corresponding increase in the KCa3.1 9 
mediated (TRAM-34 sensitive) potassium current at 24 hours and was maintained for 6 days. The 10 
upregulation of KCa3.1 was attributed to the activation of signal transduction pathways involving JAK3 11 
(janus kinase 3), Ras/Raf/MEK (mitogen-activated protein kinase)/ERK (extracellular-signal-12 
regulated kinase), and the transcription factor AP-1 (activating protein-1). T It is important to note that 13 
this study provides one of the few examples where KCa3.1 expression levels (i.e. mRNA) were correlated 14 
with an orthogonal measurement of KCa3.1 expression, in this case, measurement of the Ca
2+
 activated 15 
K
+
 current sensitive to low concentrations of TRAM-34. Most recently the same group reported KCa3.1 16 
regulation via PKG (protein Kinase G)-dependent pathways in primary rat microglia and the MLS-9 17 
microglia cell line (Ferreira et al., 2015). Using perforated-patch recordings to preserve intracellular 18 
signaling, experimental elevation of cGMP increased both the KCa3.1 current and intracellular reactive 19 
oxygen species (ROS) production. Both current and ROS were prevented by the kinase inhibitor KT5823 20 
at concentrations of 4-fold over the Ki for PKG, but only ¼ of the Ki of PKA (protein Kinase A). In MLS-9 21 
microglia the ROS-depended KCa3.1 current was also elicited by hydrogen peroxide, inhibited by N-(2-22 
mercaptopropionyl)glycine, a ROS scavenger, and prevented by a the CaMKII (Ca
2+
/calmodulin-23 
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dependent protein kinase II) inhibitor myristolated autocamtide-2 related inhibitory peptide for CaMKII  1 
(mAIP) (Ferreira et al., 2015). 2 
A study by Maezawa and colleagues demonstrated that TRAM-34 blocks amyloid beta-induced microglia 3 
proliferation, p38MAPK phosphorylation, NFκB (nuclear factor κB) activation, and nitric oxide generation 4 
in primary microglia cultures (Maezawa et al., 2011). Furthermore, TRAM-34 inhibited neurotoxic effects 5 
of amyloid beta oligomers in mixed microglia-neuron cultures and in organotypic hippocampal slices by 6 
decreasing microglial activation and partially preventing synaptic loss (Maezawa et al., 2011).  7 
Taken together, there is convincing evidence for the expression of KCa3.1 in cultured rodent microglia. 8 
While the details of regulation of KCa3.1 await confirmation with more specific tool compounds, the 9 
currently available data suggest a role for KCa3.1 at the very least in microglia ROS production and 10 
signaling. 11 
 12 
KCa3.1 EXPRESSION IN THE CNS – CURRENT DATA AND CHALLENGES 13 
KCa3.1 is widely expressed in peripheral tissues including hematopoietic cells (e.g.  erythrocytes platelets, 14 
lymphocytes, mast cells, monocytes and macrophages), fibroblasts, vascular endothelial cells and 15 
epithelial tissues (reviewed in (Wulff and Castle, 2010)). In contrast, studies reporting the cloning of 16 
KCa3.1 (hIK1, hSK4) in tissue, failed to detect its transcript in the CNS with Northern plot (Ishii et al., 17 
1997; Joiner et al., 1997). However, since then several laboratories reported in vivo KCa3.1 expression on 18 
neurons, astrocytes, oligodendrocytes, astrocytoma cells, neuroblasts, endothelial cells and in CNS 19 
tissue extracts by electrophysiology, pharmacology, PCR (polymerase chain reaction), western blot and 20 
immunostaining (Boettger et al., 2002; Bouhy et al., 2011; Chen et al., 2011; Engbers et al., 2012; King et 21 
al., 2015; Mongan et al., 2005; Turner and Sontheimer, 2014; Turner et al., 2015). Doubts remained, 22 
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however, as western blots showed unexpected sizes and contained no proper antibody controls. 1 
Furthermore, some of the results were reported as “data not shown” and many of the reports 2 
contradicted each other. Be this as it may, surprisingly none of the reports supported expression of 3 
KCa3.1 on microglia in vivo. Several investigators tried to double label KCa3.1 with microglial markers such 4 
as Iba-1, CD11b or tomato lectin, but did not detect any overlap (Bouhy et al., 2011; Turner et al., 2015). 5 
One report even went to the trouble, after not being able to detect KCa3.1 in vivo, to reconfirm KCa3.1 6 
expression in microglia and macrophages ex vivo (Bouhy et al., 2011). 7 
 8 
Further complicating the issue of whether or not KCa3.1 is expressed in the CNS, are reports on Kcnn4
-/-
 9 
mice which showed no overt behavioral or neurological phenotype (reviewed in (Wulff and Castle, 10 
2010). These observations, however, were based on gross examination and did not include detailed 11 
behavioral tests or closer neurological or neurochemical examinations. In contrast, studies on immune 12 
cells from Kcnn4
-/-
 mice displayed a loss of KCa3.1- mediated K
+
 currents and effects on cellular 13 
physiology (e.g. cytokine production) (Di et al., 2010; Lam and Wulff, 2011; Shumilina et al., 2008). 14 
However, more recent studies of KCNN4
-/-
 mice reported subtle differences in CNS monoamine levels, 15 
increased locomotor activity, alterations in the Y-maze test of working memory as well as differences in 16 
ACTH (adrenocorticotropic hormone) release in response to stress (Lambertsen et al., 2012; Liang et al., 17 
2011). Nevertheless, general brain morphology and organization of major brain regions appeared similar 18 
and immunofluorescence staining for astrocytes (GFAP) and microglia (CD11b, Iba-1) did not reveal any 19 
differences in the morphology or numbers of glial cells between genotypes (Lambertsen et al., 2012). 20 
The KCNN4
-/-
 mice were also instrumental in validating some of the KCa3.1 antibodies in peripheral 21 
tissues with known high expression levels. (SC-32949, Santa Cruz; AV35098, Sigma; ALM-051, Alamone 22 
Labs) (Chen et al., 2015b; Lambertsen et al., 2012). Based on results obtained with these antibodies, the 23 
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authors concluded that KCa3.1 is not expressed at immunohistochemically detectable levels in the 1 
unperturbed CNS in mice and in post-mortem human brain sections of cortex, cerebellum and brain 2 
stem (Lambertsen et al., 2012). Functional voltage-independent Ca
2+
 activated K
+
 currents were also not 3 
detected in patch clamp recordings from microglia in brain slices of healthy juvenile, adult and aged 4 
mice (Schilling and Eder, 2007a, 2015). 5 
In contrast to the uninjured CNS, there is evidence that microglia express KCa3.1 under pathological 6 
conditions such as ischemic injury (Chen et al., 2011). In non-infarcted areas robust KCa3.1 staining was 7 
only observed on brain microvessels. In infarcted tissue, additional KCa3.1 immunoreactivity was 8 
detected on small, round, ruffled CD68
+
 positive cells, which were presumed to be microglia or CNS-9 
infiltrating macrophages. Furthermore, multiple publications have reported beneficial effects of 10 
pharmacological inhibitors of KCa3.1 in experimental models of CNS diseases, such as experimental 11 
autoimmune encephalomyelitis (EAE), ischemic injury, traumatic brain injury, spinal cord injury, optic 12 
nerve transection and microglial CD68 reactivity associated with glioblastoma multiforme (Bouhy et al., 13 
2011; Chen et al., 2011; Chen et al., 2015b; D'Alessandro et al., 2013; Kaushal et al., 2007; Mauler et al., 14 
2004; Reich et al., 2005; Urbahns et al., 2005; Urbahns et al., 2003). 15 
Of high interest is a very recent report in which mice were subjected to middle cerebral artery occlusion 16 
with reperfusion (MCAO/R) after 8 days (Chen et al., 2015a). Microglia/macrophages were acutely 17 
isolated within 90 min with magnetic CD11b beads and subsequently investigated by electrophysiology. 18 
Microglia/macrophages from the infarcted area exhibited higher KCa3.1 current densities than microglia 19 
from non-infarcted control brains. A similar increase KCa3.1 current was seen in the brains after 20 
intraventricular LPS stimulation. Interestingly, human post mortem tissue from infarcted areas showed 21 
KCa3.1 immunoreactivity on hypertrophic, MAC387
+
 microglia/macrophages. Genetic ablation (Kcnn4
-/-
) 22 
or pharmacological blockade of KCa3.1 with TRAM-34 lead to significantly smaller infarct areas on day-8 23 
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after MCAO/R, improved neurological deficits, reduced microglia/macrophage activation assessed by 1 
Iba-1 staining and reduced brain cytokine levels (e.g. IL-1β (interleukin-1 beta) IFN-γ (interferon 2 
gamma), TGF-β1 (Transforming growth factor beta 1)) (Chen et al., 2015a). Finally, in a very elegant 3 
experiment the authors showed that TRAM-34 treatment in Kcnn4
-/- 
mice undergoing the same MCAO/R 4 
paradigm had no effect. This indicates that TRAM-34 effects were specific to KCa3.1 and suggests that 5 
KCa3.1 is a promising target for ischemic stroke (Chen et al., 2015a).  6 
Taken together, there seems to be a consensus that microglia in the unperturbed CNS do not express 7 
KCa3.1. However, Under pathological conditions, such as ischemic injury, KCa3.1 is found on rodent and 8 
most notably human CNS myeloid cells which might be microglia or infiltrating macrophages. Regardless 9 
of their nature of the KCa3.1
+
 cells, one can make an argument for KCa3.1 potential as an 10 
neuroinflammation target (Biber et al., 2016). Considering that microglia in vitro resemble a reactive 11 
phenotype and that intra ventricular LPS application induces KCa3.1 expression in vivo (Chen et al., 12 
2015a), one could speculate that in diseases with reactive microglia (Garden and Moller, 2006; Hanisch 13 
and Kettenmann, 2007; Kettenmann et al., 2011) KCa3.1 might be expressed and could be exploited as a 14 
therapeutic target. 15 
 16 
KCa3.1 INHIBITORS  17 
A number of compounds are now available to study the function of KCa3.1 channels, including toxins and 18 
pharmacological KCa3.1 blockers and activators reviewed in detail in (Wulff and Castle, 2010; Wulff et al., 19 
2007). Here we limit our discussion to the two most studied KCa3.1 inhibitors, TRAM-34 and Senicapoc 20 
(ICA-17043) with drug-like properties (Figure 1). They were synthesized based on the structure of the 21 
antifungal drug clotrimazole (Wulff et al., 2007), a potent blocker of KCa3.1 channels (Alvarez et al., 1992; 22 
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Brugnara et al., 1995; Wulff et al., 2001), that was found to be unsuitable for long-term in vivo use due 1 
to its inhibition of cytochrome P450-dependent enzymes and liver damage (Suzuki et al., 2000; Wulff 2 
and Castle, 2010; Zhang et al., 2002).  3 
 4 
TRAM-34  5 
TRAM-34 potently inhibits human KCa3.1 channels with an IC50 of 20 nM in recombinant cell lines and has 6 
no effect on cytochrome P450-dependent enzymes (Wulff et al., 2000). It has been used to investigate 7 
the physiology of KCa3.1 channels in immune cells and the involvement of KCa3.1 channels in several CNS 8 
disorders, including multiple sclerosis (Reich et al., 2005), optic nerve transaction (Kaushal et al., 2007), 9 
spinal cord injury (Bouhy et al., 2011), ischemic stroke (Chen et al., 2011; Chen et al., 2015b), and 10 
glioblastoma multiforme (D'Alessandro et al., 2013).  11 
Kaushal and colleagues showed that cultured microglia produce ROS triggering neuronal death in vitro 12 
(Kaushal et al., 2007). Using optic nerve transection as an in vivo model of neurodegeneration, intra 13 
ocular injection of TRAM-34 at day 1 and 4 after surgery attenuated neurodegeneration. Given the route 14 
of administration, total and free drug concentrations in the vitreous humor or optic nerve were not 15 
determined in this study so it is not possible to know whether sufficient free concentrations of TRAM-34 16 
were achieved to block KCa3.1 channels. That said, TRAM-34 not only significantly reduced the neuronal 17 
death following optic nerve transection, but also robustly attenuated the microglial activation as 18 
assessed by major histocompatibility complex II (MHCII) expression levels. While there are no data 19 
proving that it was indeed microglial ROS that damaged the neurons in vivo, the data are consistent with 20 
the conclusion that inhibition of KCa3.1 attenuated neurodegeneration in mice following transection of 21 
the optic nerve.  22 
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TRAM-34 has been shown to improve recovery in a model of spinal cord injury (Bouhy et al., 2011). 1 
TRAM-34 dose dependently improved locomotor function and reduced tissue loss while increasing 2 
neuron and axon sparing although only the highest dose (i.e. 120 mg/kg/day) was consistently 3 
significant. 4 
Chen and colleagues evaluated TRAM-34 in a rat model of ischemic stroke (Chen et al., 2011). After 5 
administration of TRAM-34 at 10 mg/kg, concentrations in plasma and brain peaked at approximately 6 
2.5 µmol/L between 30 minutes and 1 hour after which it fell to 59 nmol/L in plasma and 191 nmol/L in 7 
brain by 12 hours. After administration of TRAM-34 at 40 mg/kg i.p. (intraperitoneal) plasma and brain 8 
reached ~1 µmol/L at 8 hours, dropping to 0.4 µmol/L by 12 hours. When given s.c. (subcutaneous), the 9 
bio-availability of TRAM-34 was so poor that 120 mg/kg had to be administered in order to get 2.5 10 
µmol/L in plasma. Free plasma concentrations were determined to be approximately 2%. From these 11 
data, it is estimated that after 40 mg/kg i.p. at 8 hours the plasma and brain concentrations are 20 nM 12 
and 8 nM at 12 hours (before the second dose). At 10 mg/kg i.p. the free plasma and brain 13 
concentrations are estimated to be approximately 1 and 4 nM respectively. Thus the TRAM-34 14 
concentrations are at or near the IC50 values for KCa3.1 inhibition. Administration of TRAM-34 at both 10 15 
and 40 mg/kg i.p. significantly attenuated the infarct size and the degree of neuronal loss, improved the 16 
neurological deficit score and significantly reduced the extent of microglial ED1 staining. Especially 17 
promising was the finding that TRAM-34 improved the outcome in this model of stroke even when given 18 
12 hours after the ischemic insult. Current treatments need to be given within 3-4.5 hours (Adams et al., 19 
2007; Del Zoppo et al., 2009), a challenge even when the emergency room is only a short distance away. 20 
Glioblastoma multiforme (GBM) is a diffuse, highly malignant brain tumor known to express KCa3.1, 21 
which has been suspected to play a role in the infiltration of the brain paranchyma by these tumor cells, 22 
(Weaver et al., 2006).  In SCID (severe combined immunodeficiency) mice that had human GL-15 23 
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glioblastoma cells xenografted into their brains, TRAM-34 (120 mg/kg i.p.) significantly reduced tumor 1 
invasion into the host tissue (D'Alessandro et al., 2013). TRAM-34 levels in brain were determined to be 2 
approximately 1400 nM at 2 hours and 400 nM at 12 hours. Assuming that the unbound drug fraction 3 
was similar to plasma, free TRAM-34 concentrations would have been approximately 28 to 8 nM, close 4 
to the reported IC50 values for KCa3.1 inhibition. Furthermore, TRAM-34 reduced the activation of 5 
microglia (CD68 positive area) and astrocytes (GFAP positive area). In vitro TRAM-34 reduced both 6 
phagocytosis and chemotactic activity of primary microglia exposed to GBM-conditioned medium. 7 
Together, the data suggest that KCa3.1 inhibitors could be a safe and effective therapy for an otherwise 8 
difficult to treat brain tumor. 9 
TRAM-34 (10 and 40 mg/kg) was also evaluated in animal models of epilepsy (Ongerth et al., 2014). It 10 
had no effect on behavioral endpoints of the models, but significantly increased hippocampal 11 
neurodegeneration and exacerbated neuronal loss. Whether this effect is indeed related to KCa3.1 12 
inhibition or to off-target effects of TRAM-34 is currently unknown.  13 
In summary, in most studies, TRAM-34 was shown to reduce neuroinflammation and provide 14 
neuroprotection. While the effects of TRAM-34 reported in the above studies are consistent with 15 
inhibition of KCa3.1, off-target effects can not be ruled out. While selective for KCa3.1 over other calcium-16 
activated potassium channels (Wulff et al., 2000), TRAM-34 may inhibit additional targets in microglia 17 
which hinders the interpretation of these results (Schilling and Eder, 2007b). Schilling and Eder (2007b) 18 
have demonstrated that TRAM-34 blocks lysophosphatidylcholine (LPC)-induced non-selective cation 19 
current in primary microglia with a IC50 that was similar to its IC50 for KCa3.1 channels, while another 20 
presumed KCa3.1 blocker charybdotoxin had no effect on LPC signals (Schilling and Eder, 2007b). The 21 
identity of TRAM-34 sensitive channels was not determined in this study. Potential candidates could be 22 
TRPC6 (transient receptor potential cation 6) and TRPV1 (transient receptor potential vanilloid 1), both 23 
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of which are activated by LPC (Schilling and Eder, 2009). In addition, based on the similarity in structures 1 
between TRAM-34 and clotrimazole, it is possible that TRPM2 (transient receptor potential melastatin 2) 2 
channels, which are blocked by clotrimazole are also inhibited by TRAM-34 (Hill et al., 2004). Hence, 3 
TRAM-34 may modulate immune cell function by a mechanism that is unrelated to its inhibition of 4 
KCa3.1 channels and further research is needed to identify additional targets of TRAM-34. Moreover, it 5 
has recently been demonstrated that TRAM-34 still inhibits some cytochrome P450 isoforms, namely 6 
human CYP2B6, CYP2C19 and CYP3A4 with IC values in the low micromolar concentration range 7 
(Agarwal et al., 2013).  In addition, TRAM-34 shows metabolic instability and has a short half-life (~2 8 
hours in rats and primates) (Maezawa et al., 2012) complicating chronic dosing. Thus, although TRAM-34 9 
is a valuable tool compound, it has issues that may confound interpretation of mechanism in pre-clinical 10 
models and may limit its clinical utility. Because of these limitations, replication with other selective 11 
KCa3.1 inhibitors (see below) or use of genetically modified animals as done by (Chen et al., 2015a) 12 
would be very valuable. 13 
 14 
SENICAPOC (ICA-17403) 15 
Senicapoc (ICA-17043) was initially developed for the treatment of sickle cell anemia and inhibits KCa3.1 16 
channels in human erythrocytes with the IC50 of 11 nM (Ataga et al., 2006; Ataga et al., 2011; Ataga et 17 
al., 2008; Ataga and Stocker, 2009). Senicapoc works by blocking potassium efflux from erythrocytes 18 
subsequently reducing red blood cell dehydration and hemolysis (reviewed in (Wulff et al., 2007)). The 19 
drug was well tolerated in Phase 1 clinical trials in both healthy volunteers and in patients with sickle cell 20 
disease and had an average plasma half-life of 12.8 days (Ataga et al., 2006; Ataga et al., 2011). In a 21 
double blind placebo controlled Phase 2 study, Senicapoc (at 10 mg/day) reduced hemolysis and 22 
significantly increased hematocrit and hemoglobin levels in patients with sickle cell disease (Ataga et al., 23 
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2008). In a subsequent Phase 3 trial, Senicapoc was tested for its effects on vaso-occlusive pain crisis 1 
(Ataga et al., 2011). However, despite properly engaging erythrocyte KCa3.1, reducing hemolysis and 2 
increasing hemoglobin and hematocrit levels, Senicapoc had no effect on pain outcome measures and 3 
the trial was terminated (Ataga et al., 2011). While this in fact constitutes a clinical trial with negative 4 
outcome, in retrospect it seems likely that rather than a failed drug, the underlying hypothesis (i.e. 5 
reduction sickle cell dehydration and hemolysis may lead to improvements in vaso-occlusive crisis 6 
occurring during the sickle cell disease) might have been flawed.  7 
While the peripheral pharmacokinetics of Senicapoc have been described in great detail (McNaughton-8 
Smith et al., 2008), its ability to cross the blood-brain barrier was only recently investigated (Staal et al., 9 
unpublished observations). After 10 mg/kg oral dosing in rats, Senicapoc achieved free plasma 10 
concentrations of 17 nM and 65 nM and free brain concentrations of 37 and 136 nM at 1 and 4 hours 11 
post-dose respectively. Cerebro-spinal fluid (CSF) concentrations were determined to be 25 nM and 121 12 
nM at 1 and 4 hours post-dosing which are in-line with the free brain concentrations. These data suggest 13 
that Senicapoc achieves CNS concentrations are greater than its IC50 value for KCa3.1  channels and thus 14 
should be sufficient to inhibit it (McNaughton-Smith et al., 2008). In the same study, Senicapoc’s 15 
selectivity was assessed in a screen of ~70 additional related targets (Staal et al., unpublished 16 
observations). None of the targets tested was inhibited by Senicapoc at 10 µM, providing additional 17 
evidence that Senicapoc is selective for KCa3.1 channels (Staal et al., submitted). Sinacepoc was tested in 18 
the chronic constriction injury model of neuropathic pain (Bennett and Xie, 1988). Senicapoc dose 19 
dependently (10, 30 and 100 mg/kg p.o. (per os, oral administration)) attenuated the mechanical 20 
hypersensitivity induced by the peripheral nerve injury, although only the highest dose was significant. 21 
Furthermore, in contrast to reported locomotor effects in Kcnn4
-/- 
mice (Lambertsen et al., 2012), the 22 
authors did not observe any significant impact of Senicapoc on locomotor activity. This is significant as 23 
standard of care treatments for neuropathic pain, such as gabapentin and pregabalin, cause significant 24 
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sedation (Brix Finnerup et al., 2013). While the study does not shed light on the cell types in the CNS 1 
that express KCa3.1, it clearly demonstrates that Senicapoc was efficacious in ameliorating pain 2 
behaviors in rats with peripheral nerve injury and these conclusions were supported by the free drug 3 
concentrations attained in plasma, brain and CSF.  4 
 5 
NEXT STEPS FOR KCa3.1 AS A MICROGLIA TARGET 6 
The availability of Senicapoc as a clinically ready, CNS penetrant KCa3.1 inhibitor should be a 7 
considerable boost to investigations in the field. Even more so, as Senicapoc is part of the NCATS “New 8 
Therapeutic Uses” initiative (https://ncats.nih.gov/ntu/assets/2012). NCATS will provide access to the 9 
industrial partner and the asset (i.e. Senicapoc) as well as the potential for funding. Interestingly, the 10 
NCATS list of assets for repurposing has a basic assessment scale of CNS penetrance the available 11 
compounds. For Senicapoc the CNS penetrance is listed as “unknown”.  While this might have limited 12 
the interest in repurposing for CNS indications in the past, the unexpected CNS penetrance of this drug 13 
(Staal et al., unpublished observations), might provide the necessary impetus for future activities.  14 
What does the availability and CNS penetrance of Senicapoc mean for KCa3.1 as a microglia target? The 15 
available information of bona fide microglia KCa3.1 expression in CNS disorders is still limited to ischemic 16 
injury (Chen et al., 2015a). Based on the robust expression on microglia in vitro and the LPS-induced 17 
upregulation of KCa3.1 in vivo, one might speculate that other CNS disorders with disease-associated 18 
microglial phenotypes could also induce expression of KCa3.1. Such data, for example in AD, Parkinson’s 19 
and Huntington’s Disease, as well as psychiatric conditions such as depression or schizophrenia, are 20 
urgently needed. Furthermore, the availability of molecule which binds to KCa3.1 with high affinity and 21 
selectivity might provide additional options for detection of KCa3.1. Labeling these (or similar) 22 
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compounds could be an alternative to antibodies in species for which no validated antibodies are 1 
available.  2 
Taken together the currently available evidence suggests that KCa3.1 might be an interesting drug 3 
repurposing opportunity for a microglia target. In contrast to targets discussed in this GLIA Special Issue, 4 
a clinically safe and efficacious KCa3.1 blocker is readily available. KCa3.1 is in the curious position of 5 
having the validated biology lagging behind the availability of a clinically ready drug. In our mind this 6 
awards an outstanding opportunity to use Senicapoc as a chemical probe to validate microglia KCa3.1 7 
(Bunnage et al., 2013; Frye, 2010). While Senicapoc’s patent life is too short to be exploited 8 
commercially, Senicapoc is an outstanding compound to provide proof of concept data in humans. 9 
Further investigations of KCa3.1 as a target, either by academic, non-for-profit or for-profit entities will 10 
depend on the quality of proof of concept data. If experiments are carefully planned, diligently executed 11 
and judiciously interpreted (see Möller & Boddeke this GLIA Special Issue) KCa3.1 inhibitors might make 12 
targeting glial cells for CNS disorders a reality, sooner rather than later.   13 
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FIGURES 2 
Figure 1: Structures of the two KCa3.1 inhibitors TRAM-34 and Senicapoc with their IC50s for human 3 
KCa3.1 channels.  4 
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